ArticleJournal for immunotherapy of cancer2021
Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed.
- LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial.Journal for immunotherapy of cancer · 2022Trial
- Precision oncology in advanced melanoma: molecular landscapes and personalized therapy recommendations from the Molecular Tumor Board Freiburg.NPJ precision oncology · 2026Article
- Article
- Comprehensive Genomic Profiling of Acral Melanoma: Insights From the AACR Project GENIE Database.The American Journal of dermatopathology · 2026Article
- Clonal evolutionary analysis reveals patterns of malignant transformation of Intraductal Papillary Mucinous Neoplasms of the pancreas.Nature communications · 2026Article
- Identifying Robust Subclonal Structures through Tumor Progression Tree Alignment.bioRxiv : the preprint server for biology · 2026Article
- Unmasking biomarkers in small cell lung cancer: implication for precision oncology.Frontiers in oncology · 2026Review
- Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board.ESMO open · 2025Article
- Article
- Clinical and Genomic Features and Prognostic Biomarkers of Oligometastatic Nonsmall Cell Lung Cancer.Clinical lung cancer · 2025Article
- Shaping Precision Medicine: The Journey of Sequencing Technologies Across Human Solid Tumors.Biomedicines · 2025Review
- A whole-genome scan for evidence of positive and balancing selection in aye-ayes (Daubentonia madagascariensis) utilizing a well-fit evolutionary baseline model.G3 (Bethesda, Md.) · 2025Article
- The regulation of LRPs by miRNAs in cancer: influencing cancer characteristics and responses to treatment.Cancer cell international · 2025Review
- DNMT3B promotes the progression of pheochromocytoma by mediating the hypermethylation of LRP1B promoter.Epigenetics & chromatin · 2025Article
- Prognostic molecular subtype reveals the heterogeneity of tumor immune microenvironment in gastric cancer.Scientific reports · 2025Article
- Presence of RB1 or Absence of LRP1B Mutation Predicts Poor Overall Survival in Patients with Gastric Neuroendocrine Carcinoma and Mixed Adenoneuroendocrine Carcinoma.Cancer research and treatment · 2025Article
- Unveiling fatty acid subtypes: immunometabolic interplay and therapeutic opportunities in gastric cancer.Frontiers in oncology · 2025Article
- Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials.Science China. Life sciences · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundLow-density lipoprotein receptor-related protein 1b (encoded by
methodsWe conducted a multicenter, retrospective pan-cancer analysis of patients with
resultsWe identified 101 patients (44 Duke, 35 JHU, 22 UM) with
conclusionsThis multicenter study shows significantly better outcomes with ICI therapy in patients harboring P/LP versus VUS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.